Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

ASTRAZENECA

(AZN)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

AstraZeneca plc : annual earnings release

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/11/2019 | 09:15am EST

The company will report its earnings for FY 2018 on 02/14/2019. Generally, the company reports earnings better than estimates. In recent months, the 15 analysts from Thomson Reuters consensus have not revised their EPS estimates.

Annual earnings per share is expected at 1.93 USD for 2018 (- 18.4% from 2017). A summary of annual publications and estimates is available below.

Annual results2015201620172018 (e)2019 (e)
Sales
Million $
Released
Forecast
Spread
23 641
24 336
-2,9%
23 002
22 638
1,6%
22 465
21 834
2,9%

22 048

23 417
Operating income (EBITDA)
Million $
Released
Forecast
Spread
8 150
8 352
-2,4%
9 078
7 574
20%
9 891
8 207
21%

7 439

7 928
Operating profit (EBIT)
Million $
Released
Forecast
Spread
6 902
6 660
3,6%
6 721
6 455
4,1%
6 855
5 815
18%

5 819

6 276
Pre-Tax Profit (EBT)
Million $
Released
Forecast
Spread
3 069
3 146
-2,4%
3 406
2 344
45%
2 227
3 047
-27%

3 030

3 421
Net income
Million $
Released
Forecast
Spread
2 825
2 732
3,4%
3 499
2 519
39%
3 001
2 251
33%

2 495

2 793
EPS
 $
Released
Forecast
Spread
2,23
2,17
2,8%
2,77
2,18
27%
2,37
2,00
19%

1,93

2,16
Announcement Date02/04/201602/02/201702/02/2018

© MarketScreener.com 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA
02/14ASTRAZENECA : Up Over 9% After 4Q Revenue, Core EPS Beats -- Data Talk
DJ
02/14LONDON STOCK EXCHANGE : FTSE 100 squeezes out gains; ConvaTec drags midcaps
RE
02/14European shares give up three-month highs after shock U.S. data
RE
02/14LONDON MARKETS: London Stocks Cling To Gains; AstraZeneca Surges On Results
DJ
02/14ASTRAZENECA : Turns a Corner After a Decade of Struggles -- 3rd Update
DJ
02/14EUROPE MARKETS: Trade Optimism Helps European Stocks Shrug Off Growth Fears
DJ
02/14GLOBAL MARKETS LIVE : Google, Airbus, Volkswagen, Cisco…
02/14ASTRAZENECA : New cancer drugs, China give AstraZeneca welcome sales boost
RE
02/14ASTRAZENECA : Set for Growth in 2019 -- Earnings Review
DJ
02/14ASTRAZENECA : 4Q Earnings Snapshot
AQ
More news
Financials ($)
Sales 2019 23 493 M
EBIT 2019 6 206 M
Net income 2019 2 766 M
Debt 2019 14 611 M
Yield 2019 3,48%
P/E ratio 2019 36,78
P/E ratio 2020 25,73
EV / Sales 2019 4,95x
EV / Sales 2020 4,49x
Capitalization 102 B
Chart ASTRAZENECA
Duration : Period :
AstraZeneca Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 82,0 $
Spread / Average Target 2,3%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Shriti Vadera Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA4.60%101 672
JOHNSON & JOHNSON5.15%365 688
PFIZER-2.41%244 760
ROCHE HOLDING LTD.13.68%237 660
NOVARTIS7.90%231 060
MERCK AND COMPANY3.95%206 548